Life sciences licensing deals in the second quarter of 2018: updates and trends.

• Autores: P D'Souza
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 54, Nº. 10, 2018, págs. 629-638
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers and acquisitions) with a total disclosed deal value of USD 19.5 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 964 and USD 35.6 billion in the first quarter and 1,104 and USD 13.6 billion in the second quarter of 2017. Total deal value in the second quarter did not quite reach the peak of 2014 (paced by Novartis' USD 16 billion purchase of GlaxoSmithKline's oncology portfolio) but eclipsed the previous quarter primarily due to Allogene's USD 2.8 billion license for Cellectis' chimeric antigen receptor T-cell immunotherapy program for cancer.